EEN Offer - UK based manufacturer of a non-invasive medical device for the treatment of haemorrhoids seeks agents or distributors
Short summary
UK MedTech company specializing in a niche ambulatory, non-anaesthesia product that uniquely can be used to treat all four grades of haemorrhoids, seeks agents and distributors via commercial agreement
Full description
UK company has developed a novel, straightforward ambulatory, non anaesthesia procedure, that usually incurs minimal or no discomfort and can be carried out in clinical treatment rooms without the need for a dedicated operating theatre.
There is no need for sedation or anaesthetic and there is minimal recovery time, so patients can usually get back to your normal activities straightaway. Many patients feel instant relief from the moment they leave the clinic.
The company’s product provides a fast and effective electrotherapy treatment for internal haemorrhoids that has already helped thousands of haemorrhoid sufferers, for a number of years. 160,000 electrotherapy treatments have been carried out globally and in excess of 9000 treatments in the United Kingdom. The therapy is suitable for all 4 grades of haemorrhoids .
The company are actively developing the next generation of our product, which whilst is already globally unique, will have more advantages and safeguards with the application of AI capabilities from 2025 onwards.
The company are already delivering their product via commercial agreements with private clinics in the UK, and they are seeking additional agents and distributors in the EU and other global partners, to train them to deliver the service via commercial agreement.
There is no need for sedation or anaesthetic and there is minimal recovery time, so patients can usually get back to your normal activities straightaway. Many patients feel instant relief from the moment they leave the clinic.
The company’s product provides a fast and effective electrotherapy treatment for internal haemorrhoids that has already helped thousands of haemorrhoid sufferers, for a number of years. 160,000 electrotherapy treatments have been carried out globally and in excess of 9000 treatments in the United Kingdom. The therapy is suitable for all 4 grades of haemorrhoids .
The company are actively developing the next generation of our product, which whilst is already globally unique, will have more advantages and safeguards with the application of AI capabilities from 2025 onwards.
The company are already delivering their product via commercial agreements with private clinics in the UK, and they are seeking additional agents and distributors in the EU and other global partners, to train them to deliver the service via commercial agreement.
Advantages and innovation
• Unique minimally invasive treatment of all 4 grades of haemorrhoids
• Treatment can be performed in a clinical room without need for anesthetic
• Treatment is relatively pain free and is well tolerated
• Treatment is modulated and application can be titrated to the patients level of tolerance
• Patients can return to work on the same or following day
• Treatment can be performed in a clinical room without need for anesthetic
• Treatment is relatively pain free and is well tolerated
• Treatment is modulated and application can be titrated to the patients level of tolerance
• Patients can return to work on the same or following day
Technical Specification or Expertise Sought
The company are seeking agents and distributors with experience in working with private clinics, healthcare products and medtech devices.
Expected role of the partner
The company is now expanding globally as a result of its highly successful clinical treatment business in the UK. They are looking to engage with medical device distributors who share their values and are highly motivated and dynamic to bring this revolutionary treatment to market across the globe. They aim to provide a highly profitable and high demand addition to the colorectal / gastroenterology portfolios of their business partners and customers.
